<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04432714</url>
  </required_header>
  <id_info>
    <org_study_id>2019-SR-430</org_study_id>
    <nct_id>NCT04432714</nct_id>
  </id_info>
  <brief_title>Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement</brief_title>
  <official_title>A Phase II, Prospective, Single-center Study of Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prognosis of DLBCL with MYC rearrangement is dismal. Previous study showed that
      lenalidomide in combination with R-CHOP showed promising therapeutic activity and that R-DA
      EPOCH was superior compared to R-CHOP regimen in this cohort of patients. The investigators
      therefore design this phase I/II study to investigate the safety and efficacy of lenalidomide
      in combination with R-DA EPOCH in patients with untreated MYC-rearranged DLBCL.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 9, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum tolerated dose and dose limited toxicity</measure>
    <time_frame>21 days after first cycle of R2-DA-EPOCH regimen (each cycle is 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progressive free survival</measure>
    <time_frame>2 years</time_frame>
    <description>from date of inclusion to date of progression, relapse, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>from the date of inclusion to date of death, irrespective of cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>DLBCL</condition>
  <condition>Untreated</condition>
  <condition>MYC Gene Rearrangement</condition>
  <arm_group>
    <arm_group_label>R2-DA-EPOCH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1~d10# 21days a cycle</description>
    <arm_group_label>R2-DA-EPOCH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 375 mg/m2，IV, d0</description>
    <arm_group_label>R2-DA-EPOCH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide 50 mg/m2/day CI24h d1-d4</description>
    <arm_group_label>R2-DA-EPOCH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 10 mg/m2/day CI24h d1-d4</description>
    <arm_group_label>R2-DA-EPOCH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine 0.4mg/m2/day CI24h d1-d4</description>
    <arm_group_label>R2-DA-EPOCH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 750 mg/m2/day IV d5</description>
    <arm_group_label>R2-DA-EPOCH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 60 mg/m2/bid oral or IV d1-d5</description>
    <arm_group_label>R2-DA-EPOCH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed DLBCL with MYC rearrangement according to WHO 2016 criteria,
             excluding PMBCL, PCNSL, HIV-associated lymphoma.

          2. ECOG PS 0-2

          3. Age 18-60 years old

          4. Expected survival ≥ 12 weeks

          5. A measurable or evaluable disease at the time of enrolment (diameter ≥1.5cm)

          6. Understand and voluntarily sign an informed consent form, able to adhere to the study
             visit schedule and other protocol requirements.

        Exclusion Criteria:

          1. Women who are pregnant or lactating. Patients have breeding intent in 12 months or
             cannot take effective contraceptive measures during the trial measures

          2. Active hepatitis B or hepatitis C virus infection, as well as acquired, congenital
             immune deficiency diseases, including but not limited to HIV infected persons

          3. Previous exposure to any anti-tumor therapy

          4. Poor hepatic and/or renal function, defined as total bilirubin, ALT, AST, Cr more than
             two fold of upper normal level,Ccr# 50 mL/min unless these abnormalities were related
             to the lymphoma

          5. History of DVT or PE within past 12 months

          6. Poor bone-marrow reserve, defined as neutrophil count less than 1.5×109/L or platelet
             count less than 75×109/L, unless caused by bone marrow infiltration

          7. New York Heart Association class III or IV cardiac failure; or Ejection fraction less
             than 50%;or history of following disease in past 6 months: acute coronary
             syndrome#acute heart failure#severe ventricular arrhythmia

          8. CNS or meningeal involvement

          9. Known sensitivity or allergy to investigational product

         10. Major surgery within three weeks

         11. Patients receiving organ transplantation

         12. Patients with secondary tumour, excluding cured (5 years without relapse) in situ
             Non-melanoma skin cancer. superficial bladder cancer, in situ cervical cancer,
             Gastrointestinal intramucous carcinoma and breast cancer

         13. Presence of Grade III nervous toxicity within past two weeks

         14. Active and severe infectious diseases

         15. Any potential drug abuse, medical, psychological or social conditions whichmay disturb
             this investigation and assessment

         16. In any conditions which investigator considered ineligible for this study

         17. Patients with histological transformation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Xu, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Wang, M.D., Ph.D</last_name>
    <phone>86 25 68306034</phone>
    <email>lilyw7878@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Xu, M.D., Ph.D</last_name>
    <phone>86 25 68306034</phone>
    <email>xuwei10000@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital)</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Wang, M.D., Ph.D</last_name>
      <phone>86 25 68306034</phone>
      <email>lilyw7878@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Godfrey JK, Nabhan C, Karrison T, Kline JP, Cohen KS, Bishop MR, Stadler WM, Karmali R, Venugopal P, Rapoport AP, Smith SM. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 Jun 1;125(11):1830-1836. doi: 10.1002/cncr.31877. Epub 2019 Feb 1.</citation>
    <PMID>30707764</PMID>
  </reference>
  <reference>
    <citation>Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):366-378. Review.</citation>
    <PMID>27913503</PMID>
  </reference>
  <reference>
    <citation>Chamuleau MED, Burggraaff CN, Nijland M, Bakunina K, Mous R, Lugtenburg PJ, Dierickx D, van Imhoff GW, Vermaat JSP, Marijt EAF, Visser O, Mandigers C, Bilgin YM, Beeker A, Durian MF, van Rees B, Bohmer LH, Tick LW, Boersma RS, Snijders TJF, Schouten HC, Koene HR, de Jongh E, Hijmering N, Diepstra A, van den Berg A, Arens AIJ, Huijbregts J, Hoekstra O, Zijlstra JM, de Jong D, Kersten MJ. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. Haematologica. 2019 Dec 19. pii: haematol.2019.238162. doi: 10.3324/haematol.2019.238162. [Epub ahead of print]</citation>
    <PMID>31857360</PMID>
  </reference>
  <reference>
    <citation>Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.</citation>
    <PMID>30501868</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 11, 2020</study_first_submitted>
  <study_first_submitted_qc>June 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>June 13, 2020</last_update_submitted>
  <last_update_submitted_qc>June 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>WEI XU</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>DLBCL</keyword>
  <keyword>MYC Gene rearrangement</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>R-DA EPOCH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

